



Published in final edited form as:

*Stat Med.* 2009 May 15; 28(11): 1537–1553. doi:10.1002/sim.3569.

## Choosing an Optimal Method to Combine P-values

Sungho Won<sup>1</sup>, Nathan Morris<sup>2</sup>, Qing Lu<sup>2</sup>, and Robert C. Elston<sup>2</sup>

<sup>1</sup>Department of Biostatistics, Harvard School of Public Health

<sup>2</sup>Department of Epidemiology and Biostatistics, Case Western Reserve University

### Abstract

Fisher [1925] was the first to suggest a method of combining the p-values obtained from several statistics and many other methods have been proposed since then. However, there is no agreement about what is the best method. Motivated by a situation that now often arises in genetic epidemiology, we consider the problem when it is possible to define a simple alternative hypothesis of interest for which the expected effect size of each test statistic is known and we determine the most powerful test for this simple alternative hypothesis. Based on the proposed method, we show that information about the effect sizes can be used to obtain the best weights for Liptak's method of combining p-values. We present extensive simulation results comparing methods of combining p-values and illustrate for a real example in genetic epidemiology how information about effect sizes can be deduced.

### Keywords

Fisher; Liptak; effect size

## 1. INTRODUCTION

Since the first approach proposed by Fisher<sup>1</sup>, several other approaches<sup>2–5</sup> have been suggested for combining p-values. Combining p-values is usually required in one of two situations: (1) when either the values of the actual statistics that need to be combined or the forms of their distributions are unknown, or (2) this information is available, but the distributions are such that there is no known or reasonably convenient method available for constructing a single overall test<sup>6</sup>. In addition, in practical situations, combining p-values gives the statistician flexibility to weight the individual statistics according to how informative they are and allows the designs of complex experiments to be determined independently of each other.

Combining p-values has usually been used for multi-stage analyses, in which inferences are pooled using the same statistic from different samples. However, another situation has recently arisen in genetic epidemiology, which we here call multi-phase analysis. Multi-phase analysis is the process of drawing similar inferences using different statistics calculated from the same sample<sup>7–9</sup>. The null hypothesis, stated in genetic terms, is simply that a particular genomic region is not associated with the presence of disease. If this hypothesis is rejected, there is reason to seek a causal mechanism experimentally, for example using cell lines or an animal model. There are two different types of multi-phase analysis: the independent (or predictor) variables can be biologically either the same or

different, and correspondingly the statistical tests will be quite different or of the same form. For example, in genetic epidemiology, association between a marker locus and a disease can be confirmed by differences between cases and controls either in marker allele frequencies or in parameters for Hardy-Weinberg disequilibrium<sup>7, 9</sup>; in this case the same genetic marker can be the biological predictor, but the two statistics that test for association are different in form, each testing a different aspect of the distribution of marker genotypes (i.e. we have different statistics for the same biological predictor marker). Alternatively, several different genetic markers near a disease locus may be associated with the disease of interest and we perform tests of allele frequency difference between cases and controls for the alleles at each of the marker loci<sup>7, 10-14</sup>; in this case each marker locus is a different biological predictor (i.e. we use the same type of statistic to test for association with each of the marker loci). The importance of both kinds of multi-phase analysis is related to power, because power can be improved by combining the p-values of the different tests. The methods for multi-phase analysis in genetic epidemiology, for example, have so far not considered the expected genetic effects,<sup>7-9, 13, 14</sup> even though the optimal method of combining p-values depends on the magnitude of the genetic effects to be expected, and theoretical investigations on detecting genetic association has shed light on the genetic effect size expected under alternative hypotheses<sup>15, 16</sup>. Thus multi-phase analysis should be performed using this information which, because it can be determined *a priori*, allows us to choose the most powerful method for combining the p-values that these tests produce.

After Fisher introduced his  $\chi^2$ -based method, Pearson suggested an approach that has a similar, but different, rejection function. Let  $U_j$  be the p-value resulting from the  $j$ -th of  $P$  independent statistics. Whereas Fisher's method rejects the null hypothesis if and only if  $U_1 \cdot U_2 \cdot \dots \cdot U_P \leq c$ , Pearson's method rejects it if and only if  $(1 - U_1) \cdot (1 - U_2) \cdot \dots \cdot (1 - U_P) \geq c$ , where in each case  $c$  is a predetermined constant corresponding to the desired overall significance level. Wilkinson<sup>5</sup> suggested a method in which the null hypothesis is rejected if and only if  $U_j \leq c$  for  $r$  or more of the  $U_j$ , where  $r$  is a predetermined integer,  $1 \leq r \leq P$ . The approaches of Fisher and Pearson were also generalized by using the inverse of a cumulative normal distribution, and extended by Liptak to allow each test to have different weights  $w_j$ ,

where  $\sum_{j=1}^P w_j^2 = 1$ , using the combined statistic  $\sum_{j=1}^P w_j \Phi^{-1}(U_j)$ . This, if  $\Phi$  is the cumulative standard normal distribution, follows the standard normal distribution under the null hypothesis<sup>3, 17</sup>. Either the inverse of the standard error or the square root of the sample size has been suggested for the weight  $w_j$ , but we shall see that neither of these may be appropriate. Goods<sup>18</sup> suggested another function for weighting p-values,

$U_1^{w_1} U_2^{w_2} \dots U_P^{w_P}$ , where  $(\chi_{k_j}^2)^{-1}(1 - U_j)$  is the  $(1 - U_j)$ -th quantile of the chi-square

distribution with  $k_j$  degrees of freedom (DF). Lancaster<sup>19</sup> suggested  $\sum_{j=1}^P (\chi_{k_j}^2)^{-1}(1 - U_j)$  for when the  $k$ -th test has  $k_j$  DF. Koziol<sup>20</sup> showed the asymptotic equivalence of Lancaster's

and Liptak's tests when  $w_j = \sqrt{2k_j}$ . Furthermore, there have been extensions to allow for the statistics to be correlated<sup>13, 21-23</sup>. However, so far little work has been done to find the most powerful (MP) way of combining p-values and this is now becoming of increasing interest.

For a method of combining p-values to be optimal, the method needs to be uniformly MP (UMP). However, it has been shown that a UMP test does not exist because the MP test is different according to the situation<sup>6</sup>. In view of this, admissibility – which is satisfied by many of the methods and is always preserved in the UMP method – can be considered as a minimum requirement for the method to be valid. For a method of combining p-values to be admissible, if the null hypothesis is rejected for any given set of p-values  $u_j$ , then it must

also be rejected for all sets of  $v_j$  such that  $v_j \leq u_j$ . Also, even though Fisher's method was shown to be approximately most efficient in terms of Bahadur relative efficiency<sup>24</sup>, Naik<sup>25</sup> and Zaykin et al.<sup>13, 14</sup> found that Wilkinson's<sup>5</sup> method can be better than Fisher's. Here we shall show that an admissible MP test can be found for a particular situation that occurs in practice, even though there is no UMP test.

In many practical situations, the parameter spaces for both the null ( $H_0$ ) and alternative ( $H_1$ ) hypotheses can be considered simple, because the effect size is naturally assumed to be zero under the null hypothesis and there is an expected effect, or at least a minimum magnitude of effect that we would wish to detect, under the alternative hypothesis. In this situation, when the alternative hypothesis is simple, it can be shown that there is a MP test. Here we derive the MP test for a simple alternative hypothesis when we can specify this expected effect size for each alternative, and also an approximation to this test if only their ratios are available. We compare the method we derive for this situation with the previously suggested methods and show that it has optimal power as long as the prerequisites are satisfied. In section 2 we show theoretically that the most powerful method for combining p-values can be approximately achieved with information about the effect sizes; and that the parameters that are needed for existing methods of combining p-values, such as the weights in Liptak's method, should be chosen using the expected effect sizes. In section 3 we give detailed simulation results comparing the various methods in different situations, and illustrate how the information about effect sizes can be deduced for a particular type of genetic association analysis. Finally, in Section 4, we discuss extensions, including the case of correlated tests, and suggest a general strategy for combining p-values.

## 2. MOST POWERFUL REJECTION REGION

Suppose we want to combine the p-values from  $P$  tests. Let

$H_0^1: \theta_1 \in \Omega_1^N$  VS  $H_1^1: \theta_1 \in \Omega_1^A$ ,  $H_0^2: \theta_2 \in \Omega_2^N$  VS  $H_1^2: \theta_2 \in \Omega_2^A$ , ..., and  $H_0^P: \theta_p \in \Omega_p^N$  VS  $H_1^P: \theta_p \in \Omega_p^A$  be the null and alternative hypotheses for each test, respectively. The null and alternative hypotheses for combining the p-values are

$$H_0: \theta_1 \in \Omega_1^N, \theta_2 \in \Omega_2^N, \dots, \text{ and } \theta_p \in \Omega_p^N \quad \text{vs} \quad H_1: \text{not } H_0.$$

If we restrict the parameter space for the alternative hypothesis to the simple case, then the alternative is

$$H_1: \theta_1 = \theta_1^A, \theta_2 = \theta_2^A, \dots, \text{ and } \theta_p = \theta_p^A,$$

where it should be noted that some of the  $\theta_j^A$  can be in  $\Omega_j^A$  because the alternative hypothesis is that *at least one* of the  $H_0^j$  is rejected. As usual, the rejection region for any test,  $\phi$ , for combining p-values should be admissible, i.e. if  $H_0$  is rejected for any given set of  $U_j = u_j$ , then it will also be rejected for all sets of  $v_j$  such that  $v_j \leq u_j$  for each  $j$ . However,  $\phi$  is different from the usual hypothesis testing paradigm for a single parameter because, if we let the p-values from each test be  $U_1, U_2, \dots$  and  $U_P$  and they are independent, the density function of  $U_1, U_2, \dots$  and  $U_P$  under  $H_0$  must be 1. Then the Neyman-Pearson lemma results in the following, if we let  $\phi = 1$  when  $H_0$  is rejected and  $\phi = 0$  otherwise, and let  $f_A(U_1, \dots, U_P)$ ,  $T_j$  and  $A_j(U_j)$  be respectively the density function of  $U_1, U_2, \dots$  and  $U_P$  under  $H_1$ , the statistics for  $U_j$ , and a region that results in the p-value  $U_j$  for  $T_j$ :

Given  $\alpha$ , where  $0 \leq \alpha \leq 1$ , there exists  $k$  such that

$$\phi(U_1, \dots, U_p) = \begin{cases} 1 & \text{if } 1 \leq k f_A(U_1, \dots, U_p) \\ 0 & \text{if } 1 > k f_A(U_1, \dots, U_p) \end{cases} \quad \text{and } E_{H_0}(\phi(U_1, \dots, U_p)) = \alpha,$$

where independence of the statistics implies that  $f_A(U_1, \dots, U_p) = \prod_{j=1}^p f_{A,j}(U_j)$  and  $f_{A,j}(U_j)$  is  $\frac{\partial}{\partial U_j} P(T_j \in A_j(U_j); \theta_j = \theta_j^A)$ . It should be noted that  $f_{A,j}(U_j)$  is 1 if  $\theta_j^A \in \Omega_p^N$ . Admissibility requires that  $f_{A,j}(U_j)$  be a monotonic decreasing function of  $U_j$  for all  $j$ , by the following lemma:

If we let  $A_\alpha^\phi$  be the rejection region of  $\phi$  at the significance level  $\alpha$ ,  $A_\alpha^\phi$  is admissible if all the  $f_{A,j}(U_j)$  are positive monotonic decreasing functions of  $U_j$ . The proof of this lemma is trivial. As a result, by the Neyman-Pearson lemma, as long as  $f_{A,j}(U_j)$  is a monotonic decreasing function of  $U_j$  we can find an optimal test.

In general, we can define the functions  $P(T_j \in A_j(U_j); \theta_j)$  and  $f_{A,j}(U_j)$  as functions of the quantiles of the distribution of p-values. For example, if  $T_j$  is a statistic for a two-tail test that estimates a difference in means,  $se_j$  is its standard error, and the sample size is large enough, then, for some positive real constant  $c$  and denoting the cumulative standard normal distribution  $\Phi$ ,

$$P_A(T_j \in A_j(U_j); \theta_j) = \Phi(S_j - Z_{1-U_j/2}) + \Phi(-S_j - Z_{1-U_j/2})$$

$$f_{A,j}(U_j) = \frac{\partial}{\partial U_j} P_A(T_j \in A_j(U_j); \theta_j) = c \left[ \exp(Z_{1-U_j/2} S_j) + \exp(-Z_{1-U_j/2} S_j) \right],$$

where  $S_j$  is the standardized expected difference in means (i.e. the expected difference in means under  $H_1$ , divided by  $se_j$  - or  $s\hat{e}_j$  if  $se_j$  is unknown), and  $Z_U$  is the  $U$ -th quantile of the standard normal distribution. For a one-tail test,  $f_{A,j}(U_j) = c' \exp(t_j Z_{1-U_j} S_j)$ , where  $t_j$  is 1 for testing positive effects and  $-1$  for testing negative effects. Thus, the test  $\phi$  for two-tail tests becomes, by the Neyman-Pearson lemma,

$$\phi(U_1, \dots, U_p) = \begin{cases} 1 & \text{if } 1 \leq c' \prod_{j=1}^p \left[ \exp(Z_{1-U_j/2} S_j) + \exp(-Z_{1-U_j/2} S_j) \right] \\ 0 & \text{if } 1 > c' \prod_{j=1}^p \left[ \exp(Z_{1-U_j/2} S_j) + \exp(-Z_{1-U_j/2} S_j) \right]. \end{cases}$$

If the  $T_j$  include both one-tail and two-tail tests,  $\phi$  is a product of both types of  $f_{A,j}(U_j)$ . These results can be applied in a practical situation using the following Monte-Carlo algorithm, provided we have information about the expected effect sizes.

algorithm 1:

1. Generate  $z_1, \dots, z_p$  from a standardized normal distribution.
2. Confirm whether  $g_A(z_1, \dots, z_p)$  is larger than  $g_A(Z_{1-U_1/2}, \dots, Z_{1-U_p/2})$  ( $g_A(Z_{1-U_1}, \dots, Z_{1-U_p})$  if the  $T_j$  are one-side tests) and, if it is larger, add 1 to  $C$ .

After  $N$  iterations, the p-value  $C/N$ , where  $g_A(z_1, \dots, z_p) = \prod_j g_{A,j}(z_j)$ ,  $g_{A,j}(z_j) = \exp(z_j S_j) + \exp(-z_j S_j)$  for a two-tail test and  $g_{A,j}(z_j) = \exp(z_j S_j)$  ( $g_{A,j}(z_j) = \exp(-z_j S_j)$ ) for a one-tail test

of positive (negative) effect. This approach can be shown to be the same as Liptak’s method when p-values from one-tail tests are combined if  $S_j$  is used for  $w_j$ , because

$$\begin{aligned} g_A(z_1, z_2, \dots, z_p) &\leq g_A(Z_{1-U_1}, Z_{1-U_2}, \dots, Z_{1-U_p}) \\ \iff \prod_{j=1}^P \exp(t_j z_j S_j) &\leq g_A(Z_{1-U_1}, Z_{1-U_2}, \dots, Z_{1-U_p}) \\ \iff \sum_{j=1}^P t_j z_j w_j \leq c'' &\iff \sum_{j=1}^P w_j z'_j \leq c'', \end{aligned}$$

where  $w_j = S_j / \sqrt{\sum_{j=1}^P S_j^2}$ ,  $t_j$  is 1 for testing a positive effect and  $-1$  for testing a negative effect, and  $z' \sim N(0,1)$ . In addition, if only ratios of the expected differences are available, we have the following approximation:

$$\begin{aligned} g_A(z_1, z_2, \dots, z_p) &\leq g_A(Z_{1-U_1/2}, Z_{1-U_2/2}, \dots, Z_{1-U_p/2}) \\ \iff \prod_{j=1}^P [\exp(|z_j S_j|) + \exp(-|z_j S_j|)] &\leq \prod_{j=1}^P [\exp(|Z_{1-U_j/2} S_j|) + \exp(-|Z_{1-U_j/2} S_j|)] \\ \Rightarrow \prod_{j=1}^P [\exp(|z_j S_j|)] \leq c''' &\iff \sum_{j=1}^P |z_j w_j| \leq c'''. \end{aligned}$$

This can also be implemented using a Monte-Carlo algorithm, as follows.

algorithm 2:

1. Generate  $z_1, \dots$ , and  $z_p$  from a standardized normal distribution.
2. Confirm whether  $\sum_{j=1}^P |w_j z_j|$  is larger than  $\sum_{j=1}^P |w_j Z_{1-U_j/2}|$  and, if it is larger, add 1 to  $C$ .

After  $N$  iterations, the p-value  $C/N$ . Thus, the rejection region that results in the predefined significance level is similar to that of Liptak’s method if Liptak’s method uses as weight the standardized effect size instead of the square root of the sample size or the inverse of the standard error.

Also, with a slight modification, the method can be applied to statistics with other distributions, such as chi-square or F distributions. For example, if  $T_j$  follows a chi-square distribution with  $k_j$  DF, then

$$\begin{aligned} f_{A,j}(u_j) &= \left( \chi_{1-U_j}^2(k_j) \right)^{-k_j/4+1/2} I_{k_j/2-1} \left( \sqrt{\left( \chi_{k_j}^2 \right)^{-1} (1-U_j) S_j} \right), \\ I_a(x) &= \left( \frac{x}{2} \right)^a \sum_{i=0}^{\infty} \frac{(x^2/4)^i}{i! \Gamma(a+i+1)}, \end{aligned}$$

where  $S_j$  is the non-centrality parameter for  $T_j$ , and  $I_a(\cdot)$  and  $\Gamma(\cdot)$  are respectively a modified Bessel function of the first kind and a gamma function.

However, the Monte-Carlo algorithm usually requires intensive computation, which can be alleviated as follows when all the statistics are normally distributed. The combined p-value

for the p-values  $(U_1, \dots, U_P)$  is the hyper-volume of the region where  $g_A(z_1, \dots, z_p)$  is larger than  $g_A(Z_{1-U_1/2}, \dots, Z_{1-U_P/2})$  and, for any  $z_2, \dots, z_p$  that are between 0 and 1, if  $v_1$  satisfies the following inequality, then  $g_A(z_1, \dots, z_p) > g_A(Z_{1-U_1/2}, \dots, Z_{1-U_P/2})$ :

$$z_1 \leq \frac{1}{S_1} \log \frac{1}{2} \left[ k - \sqrt{k^2 - 4} \right] \text{ or } z_1 \geq \frac{1}{S_1} \log \frac{1}{2} \left[ k + \sqrt{k^2 - 4} \right] \text{ for algorithm 1,}$$

$$|z_1| \leq \frac{1}{w_1} \left[ |w_1 Z_{1-U_1}| + |w_2 Z_{2-U_2}| - |w_2 z_2| \right] \text{ for algorithm 2,}$$

where  $k = \frac{\prod_{j=1}^P g_{A,j}(Z_{1-U_j/2})}{\prod_{j=2}^P g_{A,j}(z_j)}$ . Thus, the calculation only involves being able to calculate the cumulative normal distribution and numerical integration over the above region.

### 3. COMPARISON WITH PREVIOUS METHODS

#### 3.1. Rejection regions

Several approaches to combine p-values from independent tests have been suggested but their power has not been compared. Because algorithm 1 always results in the most powerful rejection region, we compare it with the following previously suggested approaches for  $P = 2$  only:

1. Minimum p-value method: reject  $H_0$  if and only if  $\min(U_1, U_2) < c$
2. Cutoff-based method: reject  $H_0$  if and only if  $U_1 < c_1$  and  $U_2 < c_2$
3. Pearson's method : reject  $H_0$  if and only if  $(1-U_1)(1-U_2) \geq c$
4. Fisher's Method : reject  $H_0$  if and only if  $U_1 U_2 \leq c$
5. Liptak's method : reject  $H_0$  if and only if  $Z^w = (w_1 Z_{1-U_1} + w_2 Z_{1-U_2}) / \sqrt{w_1^2 + w_2^2} \geq c$  where  $Z^w \sim N(0,1)$ .

In each case  $c$  is determined by the desired value of  $\alpha$ . Figure 1 shows results for two different cases:  $S_1 = S_2 = 5$  for (a) and (b), and  $S_1 = 1, S_2 = 5$  for (c) and (d). First, when  $S_1$  and  $S_2$  are equal, the MP region is expected to be symmetric and this is seen to be the case for the rejection region of our proposed method. Also, the MP region is fairly similar to the region given by Liptak's method using  $S_1$  and  $S_2$  as weights in this case, and Liptak's approach is second best. Investigation shows that which method is second best depends on the size of  $S_1$  and  $S_2$ ; if it is less than about 3, Fisher's method is better than Liptak's method, but otherwise Liptak's is better. Second, when  $S_1$  and  $S_2$  are unequal, the MP region is expected to be asymmetric and our results confirm this. For Liptak's method, we used the weights  $1/\sqrt{26}$  and  $5/\sqrt{26}$  because the ratio between  $S_1$  and  $S_2$  is 1:5. The plot (c) and (d) in Figure 1 shows that the cutoff-based approach with  $c_1=1$  and  $c_2=0.05$  is the closest to the MP region, though Liptak's rejection region is very close to the MP region. Here the results indicate that using a more powerful statistic alone,  $T_2$  in this case, is better than combining the two together using Liptak's method.

#### 3.2. Simulation when the standardized expected difference is known

We applied our approach to the mean difference test of two samples when the standardized expected difference is known. For two different test statistics, we generated  $X_{i1}, X_{i2}, Y_{k1}$  and  $Y_{k2}$  ( $i = 1, 2, \dots, N_1$  and  $k = 1, \dots, N_2$ ) as follows:

$$\begin{aligned} X_{i1} &= \varepsilon_{i1}, & X_{i2} &= \mu_x + \varepsilon_{i2}, \\ Y_{k1} &= \varepsilon_{k1}, & Y_{k2} &= \mu_y + \varepsilon_{k2}, \end{aligned}$$

where  $\mu_x$  and  $\mu_y$  are either 0.1 or 0.02,  $\varepsilon_{il}$  and  $\varepsilon_{il}'$  ( $l = 1, 2$ ) independently follow normal distribution with mean 0 and variance 0.5. The  $t$ -statistic approximately follows a normal distribution if the sample size is large enough. Thus, we obtain the following function for our suggested approach:

$$g_A(z_1, z_2) = \prod_{j=1}^2 \left[ \exp(z_j S_j) + \exp(-z_j S_j) \right]$$

where  $S_1 = \mu_x \sqrt{N_1}$  and  $S_2 = \mu_y \sqrt{N_2}$ .

Figure 2 shows the power results of a simulation with various sample sizes for four different cases and they are calculated from 5000 replicate samples: **(a)**  $\mu_x = \mu_y = 0.1$  and  $N_1 = N_2$ , **(b)**  $\mu_x = \mu_y = 0.1$  and  $N_1 = 5N_2$ , **(c)**  $\mu_x = \mu_y = 0.02$  and  $N_1 = N_2$  and **(d)**  $\mu_x = \mu_y = 0.02$  and  $N_1 = 5N_2$ . In each case we compare our proposed method with Fisher's and Liptak's methods. First, even though the three approaches have similar power when  $S_1 = S_2$ , the proposed method has the best empirical power, followed by Liptak's method and then by Fisher's for case **(a)**, but followed by Fisher's method and then by Liptak's for case **(c)**. As we mentioned before, Liptak's method is better than Fisher's if the standardized expected effect size is larger than about 3, and otherwise Fisher's is better; the range of  $S_j$  considered for the simulation is from 2.2 to 5 for case **(a)** and from 0.4 to 1 for case **(c)**. Second, if  $S_1$  and  $S_2$  are different (we considered the ratio 5:1), Fisher's is the worst method and Liptak's method using  $S_1$  and  $S_2$  as weights is approximately equal to our proposed method.

### 3.3. Simulation for a multi-stage analysis with estimated standard error

As mentioned above, methods for combining p-values can be used for both multi-stage analysis and multi-phase analysis. We applied our approach to testing the mean difference between two samples for multi-stage analysis, i.e. pooling the results of using the same statistic from different samples, when the standard deviation is unknown. In general, because multi-stage analyses (including meta-analysis) are usually for the same hypothesis, we can assume the same expected difference under the alternative hypothesis but the sample sizes or variances could be different. We therefore applied our approach to test a mean difference from simulated samples with different sample sizes and with different variances, using numerical integration for the proposed method of combining the p-values. For two different test statistics, we generated  $X_{i1}, X_{i2}, Y_{k1}$  and  $Y_{k2}$  ( $i = 1, 2, \dots, N_1$  and  $k = 1, \dots, N_2$ ) as follows:

$$\begin{aligned} X_{i1} &= \varepsilon_{i1}, & X_{i2} &= \mu + \varepsilon_{i2}, & \varepsilon_{il} &\sim N(0, \sigma_1^2) \\ Y_{k1} &= \varepsilon_{k1}, & Y_{k2} &= \mu + \varepsilon_{k2}, & \varepsilon_{kl} &\sim N(0, \sigma_2^2), \end{aligned}$$

where  $\varepsilon_{il}$  and  $\varepsilon_{il}'$  ( $l = 1, 2$ ) are independent. Because the  $t$ -statistic approximately follows a normal distribution if the sample size is large enough, we obtain the following functions:

$$g_A(z_1, z_2) = \prod_{j=1}^2 [\exp(z_j S_j) + \exp(-z_j S_j)] \quad \text{for algorithm 1}$$

$$g_A(z_1, z_2) = \prod_{j=1}^2 |z_j w_j| / \sqrt{w_1^2 + w_2^2} \quad \text{for algorithm 2,}$$

where  $S_1 = \mu' / s\hat{e}_1$ ,  $S_2 = \mu' / s\hat{e}_2$ ,  $w_j = \widehat{se}_j^{-1}$  and  $\mu'$  is the expected difference under the alternative hypothesis. It should be noted that in this case  $w_j$  depends only on the standard error. We also applied Fisher's method and Liptak's method using as weights the inverse of the standard error (Liptak1) and the square root of the sample size (Liptak2).

Table 1 shows the empirical type I error from 10,000 replicate samples as a function of  $N_2$  when we assume  $\sigma_1^2 = \sigma_2^2 = 1$  and  $N_1$  is 1000.  $\mu$  and  $\mu'$  are assumed to be 0 and 0.05 respectively. The results show that all methods preserve type I error well at the significance level 0.05. Table 2 and Table 3 show the empirical power based on 5,000 replicate samples when equal variances but different sample sizes are assumed, and when equal sample sizes but different variances are assumed. In both cases,  $\mu$  and  $\mu'$  are equal to 0.05. For Table 2, we assume that  $\sigma_1^2 = \sigma_2^2 = 1$  and  $N_2 = 600, 700, 800, \dots, 1900$  and 2000 while  $N_1$  is fixed at 1000, and for Table 3,  $N_1 = N_2 = 1000$  and  $\sigma_2^2 = 1, 2, \dots, 10$  while  $\sigma_1^2$  is 1. In Table 2, algorithm 1 shows the best result, followed by algorithm 2. Fisher's method is better than the Liptak methods when  $N_2$  is similar to  $N_1$  but otherwise the Liptak methods are better. Liptak 1 and Liptak 2 have similar empirical power because the weights for both are similar. In Table 3, we find similar results except that Liptak 1 is much better than Liptak 2 because the weights for Liptak 2 are not close to the standardized expected differences. Thus, we conclude that algorithm 1 is always the most powerful when we have information about the expected differences, but no information about the variances, and the same power can be approximately achieved with only their ratios using algorithm 2.

### 3.4. Simulation for multi-phase analysis with estimated standard error

We also applied our approach to the mean difference test of two samples for multi-phase analysis when the standard deviation is unknown. Here we assume that the expected differences are known either from previous studies or on the basis of theoretical results that allow us to know their ratios, as can occur in genetic epidemiology 15·16 . Again for two different test statistics, we generated  $X_{i1}, X_{i2}, Y_{k1}$  and  $Y_{k2}$  ( $i = 1, 2, \dots, N_1$  and  $k = 1, \dots, N_2$ ) as follows:

$$\begin{aligned} X_{i1} &= \varepsilon_{i1}, & X_{i2} &= \mu_x + \varepsilon_{i2}, \\ Y_{k1} &= \varepsilon_{k1}, & Y_{k2} &= \mu_y + \varepsilon_{k2}, \end{aligned}$$

where  $\varepsilon_{il}$  and  $\varepsilon_{il}'$  ( $l = 1, 2$ ) independently follow normal distributions with mean 0 and variance 1. For large sample sizes, we obtain the following function for our proposed approach:



$$g_A(z_1, z_2) = \prod_{j=1}^2 \left[ \exp(z_j S_j) + \exp(-z_j S_j) \right] \quad \text{for algorithm 1}$$

$$g_A(z_1, z_2) = \prod_{j=1}^2 |z_j w_j| / \sqrt{w_1^2 + w_2^2} \quad \text{for algorithm 2,}$$

where  $S_1 = \mu_X'/s\hat{e}_1$ ,  $S_2 = \mu_Y'/s\hat{e}_2$ ,  $w_j = S_j$ , and  $\mu_X'$  and  $\mu_Y'$  are the expected differences under the alternative hypothesis. For Liptak's method, we again used as weights these  $w_j$  (Liptak1) and the inverse of the standard error (Liptak2). For both algorithms, the combined p-values were calculated using numerical integration.

Table 4 shows the results of a simulation with 10,000 replicate samples when  $N_1=N_2=1,000$  and  $\sigma_1^2=\sigma_2^2=1$ . For empirical type I error,  $\mu_X$  and  $\mu_Y$  are assumed to be 0 for simulating  $X_{il}$  and  $Y_k$ , and the empirical type I errors calculated at the nominal 0.05 significance level. For  $S_1$  and  $S_2$ ,  $\mu_X'$  is assumed to be 0.05 and we consider 0.01, 0.02, ... and 0.15 for  $\mu_Y'$ . The results show that both algorithm 1 and algorithm 2 preserve the type I error well, as in multi-stage analysis. Table 5 shows the results of a simulation with 5,000 replicate samples at the 0.05 significance level when  $N_1=N_2=1,000$  and  $\sigma_1^2=\sigma_2^2=1$ . For empirical power,  $\mu_X$  and  $\mu_Y$  were assumed equal to  $\mu_X'$  and  $\mu_Y'$ , respectively,  $\mu_X$  was assumed to be 0.05 and we considered 0.01, 0.02, ..., 0.15 for  $\mu_Y$ . The results show that algorithm 1 generally has the best power, followed by algorithm 2. Also, the proposed algorithms are always better than the Liptak methods and Fisher's method, though the difference is not large. Finally, Liptak's method is better than Fisher's method if the  $S_j$  are used as weights and  $\mu_X$  and  $\mu_Y$  are not similar, which confirms first that Fisher's method is usually good when the standardized expected differences are similar and small, and second that Liptak's method should use the standardized expected differences as weights, as in algorithm 2.

### 3.5 A genetic multi-phase example

The simulation results in sections 3.3 and 3.4 demonstrate the increase in power possible, but do not illustrate exactly how the effect sizes could be obtained in practice, nor do they examine the sensitivity of the method to assumptions made about those effect sizes. We illustrate this here for one particular genetic example of multi-phase analysis.

In genetic epidemiology, the Cochran-Armitage (CA) trend is usually used for association analysis in a case-control design assuming the two alleles of a diallelic marker act in an additive manner on disease susceptibility<sup>26</sup>. The test for Hardy Weinberg proportions (HWP) in cases has been combined with the CA test in an attempt to improve the statistical power for association analysis by using either Fisher's method<sup>7</sup> or a cutoff-based method<sup>9</sup>, which was called self-replication. However, combining these two tests sometimes leads to a reduction in power<sup>11</sup>. We now show that if we use the expected effect size information the power is improved with either algorithm 2 or Liptak's method, and explain why, without using this information, combining these two tests sometimes fails to increase power.

For a disease locus  $D$  with disease allele  $D_1$  and normal allele  $D_2$ , let  $P_{D_k|case}$  and  $P_{D_k|cont}$  be the frequencies of allele  $D_k$  in the case group and control group, respectively, and let  $P_{D_k D_k|case}$  and  $P_{D_k D_k|cont}$  be the analogous frequencies of the genotype  $D_k D_k$ . As a measure of Hardy Weinberg disequilibrium (HWD) in cases, let  $d_{A|case} \equiv P_{A_1 A_1|case} - (P_{A_1|case})^2$ . If we let  $\phi$  and  $\phi_l$  be the disease prevalence and the penetrance of disease genotype  $l$  at the disease location, the expected sizes of these quantities are<sup>16, 27</sup>:

$$P_{A_1|case} - P_{A_1|cont} = P_{D_1} P_{D_2} \left[ \frac{1}{\phi} - \frac{1}{1-\phi} \right] \left[ P_{D_1} (\phi_{D_1 D_1} - \phi_{D_1 D_2}) + P_{D_2} (\phi_{D_1 D_2} - \phi_{D_2 D_2}) \right] \text{ and}$$

$$d_{A_1|case} = P_{A_1|A_1|case} - P_{A_1|case}^2 = \frac{(\phi_{D_1 D_1} \phi_{D_2 D_2} - \phi_{D_1 D_2}^2) P_{D_1}^2 P_{D_2}^2}{\phi^2}.$$

If the disease genotype effect is small, we can assume that  $\phi_{D_2 D_2} / \phi \approx 1$  and then, for a rare disease with known mode of inheritance we have

$$P_{D_1|case} - P_{D_1|cont} = P_{D_1} P_{D_2} \left[ \frac{1}{\phi} - \frac{1}{1-\phi} \right] \left[ P_{D_1} (\phi_{D_1 D_1} - \phi_{D_1 D_2}) + P_{D_2} (\phi_{D_1 D_2} - \phi_{D_2 D_2}) \right]$$

$$\approx \frac{P_{D_1} P_{D_2}}{\phi} \left[ P_{D_1} (\phi_{D_1 D_1} - \phi_{D_1 D_2}) + P_{D_2} (\phi_{D_1 D_2} - \phi_{D_2 D_2}) \right]$$

$$\approx P_{D_1} P_{D_2} \left[ P_{D_1} (\lambda_2 - \lambda_1) + P_{D_2} (\lambda_1 - 1) \right],$$

and  $d_{D_1|case} \approx P_{D_1}^2 P_{D_2}^2 (\lambda_2 - \lambda_1^2)$ , where  $\lambda_1$  is the heterozygous disease genotype relative risk and  $\lambda_2$  is the homozygous disease genotype relative risk (i.e. relative to the homozygous genotype containing no disease predisposing allele). Thus, for a recessive disease we have

$$(P_{D_1|case} - P_{D_1|cont}) : d_{D_1|case} \approx 1 : P_{D_2}.$$

Also, we have  $(P_{D_1|case} - P_{D_1|cont}) : d_{D_1|case} \approx 1 : \lambda_2 P_{D_1} \approx 1 : P_{D_1}$  and  $d_{D_1|case} = 0$  respectively, for dominant and multiplicative modes of inheritance. Because additive and multiplicative disease inheritance have similar  $\lambda_1$ , we can conclude that the HWP test in cases is non-informative for additive and multiplicative diseases, but can improve the CA test for dominant and recessive diseases, with the above expected ratios of effect sizes.

Figure 3 and Figure 4 show the empirical power from 10,000 replicate samples at the significance level 0.05 when the disease modes of inheritance are dominant and recessive, respectively. We assume the disease allele frequency is 0.2, and the numbers of cases and controls are equal. For the weights,  $w_1$  and  $w_2$ , in algorithm 2 and Liptak's method, we used

$$1/(\widehat{P}_{D_1|case} - \widehat{P}_{D_1|cont}) \text{ and } (\widehat{P}_{D_2|case} + \widehat{P}_{D_2|cont}) / \widehat{d}_{D_1|case} \text{ for the recessive disease}$$

$$1/(\widehat{P}_{D_1|case} - \widehat{P}_{D_1|cont}) \text{ and } (\widehat{P}_{D_1|case} + \widehat{P}_{D_1|cont}) / \widehat{d}_{D_1|case} \text{ for the dominant disease}$$

divided by their estimated standard errors; and algorithm 1 is not considered because only ratios of the effect sizes are available. For the cutoff-based method, the value of  $c_1$  that results in the maximal empirical power (among the values 0.05, 0.1, ..., 0.95) was used. A one-tail test was applied for the HWP test because it is known, if the disease-predisposing allele is the less common allele, that  $d_{D_1|case} > 0$  for a recessive disease and  $d_{D_1|case} < 0$  for a dominant disease<sup>28</sup>. The results show that algorithm 2 and Liptak's method are similar, because algorithm 2 is equal to Liptak's method in the case of a one-tail test. However, the results also confirm that the other methods that have been used to combine the CA and HWP tests are not as powerful as the proposed methods. Also, it should be noted that algorithm 2 and Liptak's method using the proposed weights work well even though the proposed weights are not the true effect sizes, and the CA and HWP tests are not strictly independent under the alternative hypothesis. In particular, the empirical power at  $\lambda_2 = 1$  is equivalent to the empirical type I error at significance level 0.05, and it is seen that both algorithm 2 and Liptak's method using the proposed weights preserve this type I error.

## 4. DISCUSSION

Over the last few decades, the UMP region for combining p-values has been sought and it has been proved that there is no UMP test. Because of this, the various combination methods were compared empirically instead of by further theoretical investigation. However, all these investigations failed to find any practically MP region. Here we have shown that a MP test can be found if we specify the expected effect sizes, or it can be approximated if we only know their ratios. Also, our results show that this proposed method always has the best power, though the power may not be substantially larger than that of other methods. We have illustrated the method with a genetic example that demonstrated moderately increased power, even when the ratio of effect sizes was misspecified.

Although the proposed algorithms described here are for independent tests with underlying normal distributions, they can also be extended to other cases, such as the  $T_j$  follow different distributions or, for example, a multivariate normal distribution with correlations. If the statistic  $T_j$  for each p-value follows a different distribution, a factor  $g_{A_j}(\cdot)$  appropriate for each  $T_j$  should be used in the Monte-Carlo algorithm, instead of only factors of the form  $\exp(z_j S_j) + \exp(-z_j S_j)$ . In addition, when the statistics  $T_j$  for each p-value follow a multivariate normal distribution (MVN), the  $g_A(\cdot)$  for the MVN density should be used in step (2) after sampling from the standard MVN distribution with appropriate correlations between the  $T_j$  under the null hypothesis. Thus, with some slight modification the same approach can be extended to complex cases.

Though the proposed method improves power, the need to have information about the expected effect sizes could limit its application. However, hypothesis testing for combining p-values should not be understood in the same way as for testing parameters because there is no uniformly most powerful method and the statistical power can be substantially different according to the situation. Instead, it would be better to use information about effect sizes, something that is often available, especially – as we have shown – in genetic epidemiology. The proposed method suggests the following general strategy for its application in practice:

1. If the effect sizes are known, the proposed method using the expected differences (algorithm 1) will give the best power.
2. If only the ratios between the effect sizes are available, the proposed method using their ratios (algorithm 2) should be considered. To avoid excess computation, Liptak's method using as weights ratios of the standardized effect sizes can be used when the expected differences are different.
3. If precise information is not available but the effect sizes are expected to be small (large), Fisher method (Liptak's method using equal weights) should be used.

Alternatively, if we consider other methods, such as a cutoff-based method (which is sometimes called self-replication or screening 8·9), instead of Liptak's method or the proposed method,  $c_1$  and  $c_2$  should be determined by the ratios of the standardized effect sizes. Sometimes nothing is available about effect sizes, but the effect sizes can nevertheless be expected to be equal. For example, in a meta-analysis, we usually want to combine results from several studies for the same hypothesis. Then we suggest using inferences based on ratios between the standard errors because  $S_1:S_2=1/\hat{\sigma}_1:1/\hat{\sigma}_2$ . Finally, it should be remembered that Liptak's method with appropriate weights is the same as our proposed method if the p-values are from one-tail tests.


## Acknowledgments

This work was supported in part by a U.S. Public Health Research grant (GM28356) from the National Institute of General Medical Sciences, Cancer Center Support grant (P30CAD43703) from the National Cancer Institute, and Training grant (HL07567) from the National Heart, Lung and Blood Institute.


## Reference List

1. Fisher, RA. *Statistical Methods for Research Workers*. London: Oliver & Boyd; 1950. p. 99-101.
2. George EO, Mudholkar GS. On the Convolution of Logistic Random Variables. *Metrika*. 1983; 30:1–14.
3. Liptak T. On the combination of independent tests. *Magyar Tud.Akad.Mat.Kutato' Int.Ko"zl*. 1958; 3:171–197.
4. Pearson ES. The probability integral transformation for testing goodness of fit and combining independent tests of significance. *Biometrika*. 1938; 30(1):134–148.
5. Wilkinson B. A statistical consideration in psychological research. *Psychological Bulletin*. 1951; 48:156–157. [PubMed: 14834286]
6. Birnbaum A. Combining independent tests of significance. *J Am Stat Assoc*. 1954; 49(267):559–574.
7. Hoh J, Wille A, Ott J. Trimming, weighting, and grouping SNPs in human case-control association studies. *Genome Res*. 2001; 11(12):2115–2119. [PubMed: 11731502]
8. Van Steen K, McQueen MB, Herbert A, Raby B, Lyon H, Demeo DL, Murphy A, Su J, Datta S, Rosenow C, Christman M, Silverman EK, Laird NM, Weiss ST, Lange C. Genomic screening and replication using the same data set in family-based association testing. *Nat.Genet*. 2005; 37(7):683–691. [PubMed: 15937480]
9. Zheng G, Song K, Elston RC. Adaptive two-stage analysis of genetic association in case-control designs. *Hum.Hered*. 2007; 63(3–4):175–186. [PubMed: 17310127]
10. Dudbridge F, Koeleman BP. Rank truncated product of P-values, with application to genomewide association scans. *Genet.Epidemiol*. 2003; 25(4):360–366. [PubMed: 14639705]
11. Hao K, Xu X, Laird N, Wang X, Xu X. Power estimation of multiple SNP association test of case-control study and application. *Genet.Epidemiol*. 2004; 26(1):22–30. [PubMed: 14691954]
12. Yang HC, Lin CY, Fann CS. A sliding-window weighted linkage disequilibrium test. *Genet.Epidemiol*. 2006; 30(6):531–545. [PubMed: 16830340]
13. Zaykin DV, Zhivotovsky LA, Westfall PH, Weir BS. Truncated product method for combining P-values. *Genet.Epidemiol*. 2002; 22(2):170–185. [PubMed: 11788962]
14. Zaykin DV, Zhivotovsky LA, Czika W, Shao S, Wolfinger RD. Combining p-values in large-scale genomics experiments. *Pharm.Stat*. 2007; 6(3):217–226. [PubMed: 17879330]
15. Abecasis GR, Cardon LR, Cookson WO. A general test of association for quantitative traits in nuclear families. *Am J Hum Genet*. 2000; 66(1):279–292. [PubMed: 10631157]
16. Won S, Elston RC. The power of independent types of genetic information to detect association in a case-control study design. *Genet.Epidemiol*. 2008 In press.
17. Zheng, G.; Milledge, T.; George, EO.; Narasimhan, G. *Lecture Notes in Computer Science*. Springer: Berlin Heidelberg. Vol. 3992. 2006. Pooling Evidence to Identify Cell Cycle-Regulated Genes; p. 694-701.
18. Goods IJ. On the Weighted Combination of Significance Tests. *J R Stat Soc B*. 1955; 17(2):264–265.
19. Lancaster HO. The combination of probabilities: an application of orthonormal functions. *Austral.J.Stat*. 1961; 3:20–33.
20. Koziol JA. A note on Lancaster's procedure for the combination of independent events. *Biom.J*. 1996; 38(6):653–660.
21. Delongchamp R, Lee T, Velasco C. A method for computing the overall statistical significance of a treatment effect among a group of genes. *BMC.Bioinformatics*. 2006; 7 Suppl 2:S11. [PubMed: 17118132]


22. Dudbridge F, Koeleman BP. Efficient computation of significance levels for multiple associations in large studies of correlated data, including genomewide association studies. *Am J Hum Genet.* 2004; 75(3):424–435. [PubMed: 15266393]
23. Lin DY. An efficient Monte Carlo approach to assessing statistical significance in genomic studies. *Bioinformatics.* 2005; 21(6):781–787. [PubMed: 15454414]
24. Littell RC, Folks L. Asymptotic Optimality of Fisher's method of combining independent tests. *J Am Stat Assoc.* 1971; 66(336):802–806.
25. Naik UD. The equal probability tests and its applications to some simultaneous inference problems. *J Am Stat Assoc.* 1969; 64(327):986–998.
26. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007; 447(7145):661–678. [PubMed: 17554300]
27. Nielson DM, Ehm MG, Weir BS. Detecting marker-disease association by testing for Hardy-Weinberg disequilibrium at a marker locus. *Am J Hum Genet.* 1999; 63(5):1531–1540.
28. Zheng G, Ng HK. Genetic model selection in two-phase analysis for case-control association studies. *Biostatistics.* 2008; 9(3):391–399. [PubMed: 18003629]



**Figure 1. Rejection regions for five methods of combining two P-values at the 0.05 significance level**  
 Two different cases are considered: the standardized effect sizes under  $H_1$  are equal (a) and unequal (c). Because the proposed method is the most powerful, we can compare the methods that have been suggested by comparing the closeness of their rejection regions to that of our proposed method.




**Figure 2. Empirical power as a function of the sum of the sample sizes for two p-values**  
 The empirical power at the 0.01 significance level is calculated, in each case for total sample sizes 1000, 2000, 3000, 4000, and 5000, obtained from a simulation of 5000 replicate samples, as a function of the sum of the sample sizes; for algorithm 1, 100,000 Monte Carlo replicates were used. Two different cases are considered: the standardized effect sizes under  $H_1$  are equal, (a) and (c), and unequal (b) and (d).



**Figure 3. Empirical power for a dominant disease**

The CA and HWP test p-values are combined using algorithm 2, Fisher’s method, Liptak’s method, and the best cutoff-based method, compared to the CA test alone. The empirical power at the significance level 0.05 is calculated from 10,000 replicate samples; for algorithm 2, 50,000 Monte Carlo replicates were used.





**Figure 4. Empirical power for a recessive disease**

The CA and HWP test p-values are combined using algorithm 2, Fisher’s method, Liptak’s method, and the best cutoff-based method, compared to the CA test alone. The empirical power at the significance level 0.05 is calculated from 10,000 replicate samples; for algorithm 2, 50,000 Monte Carlo replicates were used.

Table 1

**Empirical type I error for multi-stage analysis**

The empirical type I error at the significance level 0.05 is calculated from 10,000 replicate samples, in each case for  $N_2=600, 200, 300, \dots, 1900$  and 2000. For algorithm 1,  $\mu'$  is assumed to be 0.05 for  $S_j$ , and for simulating  $X_{it}$  and  $Y_{kt}$   $\mu$  is assumed to be 0. Liptak's method uses as weights the inverse of the standard error (Liptak1) and the square root of the sample size (Liptak2); for algorithms 1 and 2, numerical integration was used.

$N_2$	Fisher	Liptak1	Liptak2	alg. 1	alg. 2
600	0.052	0.0524	0.0524	0.0526	0.0532
700	0.0531	0.0479	0.0502	0.0513	0.0518
800	0.0471	0.0507	0.0479	0.0472	0.0471
900	0.0512	0.0501	0.0502	0.0499	0.05
1000	0.0505	0.052	0.0522	0.0499	0.0498
1100	0.0528	0.0503	0.0522	0.0532	0.0526
1200	0.0508	0.0521	0.0502	0.0505	0.0499
1300	0.053	0.049	0.0518	0.0534	0.0529
1400	0.0507	0.0499	0.049	0.0498	0.0503
1500	0.0505	0.0521	0.0503	0.051	0.0497
1600	0.0542	0.05	0.052	0.0523	0.0519
1700	0.496	0.0501	0.0501	0.0514	0.0504
1800	0.473	0.05	0.0499	0.497	0.0489
1900	0.497	0.0485	0.0482	0.474	0.478
2000	0.502	0.0505	0.0508	0.0488	0.495

**Table 2**  
**Empirical power for multi-stage analysis for different sample sizes**

The empirical power at the significance level 0.05 is calculated from 5,000 replicate samples, for  $N_2=600, 200, 300, \dots, 1900$  and 2000. For algorithm 1, both  $\mu$  and  $\mu'$  are assumed to be 0.05 for simulating  $X_{it}$  and  $Y_{kt}$ . and  $S_j$  in algorithm 1; for algorithms 1 and 2, numerical integration was used. Liptak's method uses as weights the inverse of the standard error (Liptak1) and the square root of the sample size (Liptak2).

$N_2$	Fisher	Liptak1	Liptak2	alg. 1	alg. 2
600	0.2338	0.2332	0.2316	0.2376	0.234
700	0.2392	0.235	0.2356	0.2412	0.2402
800	0.2454	0.2414	0.2418	0.2488	0.2464
900	0.2574	0.2474	0.2468	0.2574	0.2522
1000	0.2834	0.2792	0.2796	0.283	0.2822
1100	0.291	0.2872	0.287	0.2946	0.29
1200	0.3042	0.302	0.303	0.3078	0.3074
1300	0.3158	0.3146	0.3158	0.3234	0.3214
1400	0.3266	0.326	0.3262	0.329	0.328
1500	0.3362	0.3354	0.3354	0.343	0.3428
1600	0.3356	0.3334	0.3328	0.3468	0.3434
1700	0.3598	0.3592	0.3592	0.3662	0.3652
1800	0.3694	0.3688	0.3688	0.3824	0.3804
1900	0.3842	0.3876	0.3862	0.3954	0.3976
2000	0.3998	0.4074	0.4064	0.4144	0.415

**Table 3**  
**Empirical power for multi-stage analysis with different variances**

The empirical power at the significance level 0.05 is calculated from 5,000 replicate samples, for  $\sigma_2^2=1, 2, 3, \dots, 9$  and 10. For algorithm 1, both  $\mu$  and  $\mu'$  are assumed to be 0.05 for simulating  $X_{ij}$  and  $Y_{ki}$ , and  $S_j$  in algorithm 1; for algorithms 1 and 2, numerical integration was used. Liptak's method uses as weights the inverse of the standard error (Liptak1) and the square root of the sample size (Liptak2).

$\sigma_2^2$	Fisher	Liptak1	Liptak2	alg. 1	alg. 2
1	0.2846	0.2716	0.2726	0.283	0.2798
2	0.1966	0.195	0.186	0.2088	0.2016
3	0.1848	0.1974	0.1824	0.2046	0.2018
4	0.1778	0.1876	0.1644	0.2006	0.1924
5	0.1818	0.2016	0.1676	0.2126	0.2066
6	0.174	0.2004	0.1604	0.2058	0.2054
7	0.1628	0.19	0.1486	0.1988	0.1926
8	0.1702	0.189	0.152	0.1932	0.192
9	0.1716	0.201	0.1584	0.2092	0.2068
10	0.1738	0.2062	0.154	0.2134	0.2096

Table 4

**Empirical type I error for multi-phase analysis**

The empirical type I error at the significance level 0.05 is calculated from 10,000 replicate samples for multi-phase analysis, for  $\mu_Y' = 0.01, 0.02, 0.03, \dots, 0.14$  and 0.15. Both  $\mu_X$  and  $\mu_Y$  are assumed to be 0 for simulating  $X_{it}$  and  $Y_{it}$ , and  $\mu_X'$  is equal to 0.05 for algorithm 1. Liptak's method uses as weights the standardized expected difference with the standard error estimated (Liptak1) and the inverse of the standard error (Liptak2); for algorithms 1 and 2, numerical integration was used.

$\mu_Y'$	Fisher	Liptak1	Liptak2	alg. 1	alg. 2
0.01	0.0512	0.0515	0.052	0.0514	0.0531
0.02	0.0489	0.0497	0.0481	0.0496	0.0508
0.03	0.0505	0.0501	0.0512	0.0498	0.0496
0.04	0.0541	0.0545	0.0551	0.0555	0.0539
0.05	0.0495	0.0485	0.0483	0.0483	0.0479
0.06	0.0483	0.0477	0.0481	0.0476	0.0483
0.07	0.047	0.0461	0.046	0.0469	0.0466
0.08	0.0483	0.0494	0.0502	0.0495	0.0501
0.09	0.0504	0.0473	0.0503	0.0483	0.048
0.10	0.0477	0.048	0.0492	0.0481	0.0476
0.11	0.0498	0.0516	0.0512	0.0513	0.0524
0.12	0.0482	0.0471	0.0466	0.049	0.0467
0.13	0.0467	0.0462	0.0486	0.0481	0.0476
0.14	0.0543	0.0522	0.0534	0.0518	0.0519
0.15	0.0524	0.0523	0.0508	0.0516	0.0521

Table 5

**Empirical power for multi-phase analysis**

The empirical power at the significance level 0.05 is calculated from 5,000 replicate samples for  $\mu_Y=0.01, 0.02, 0.03, \dots, 0.14$  and 0.15. Both  $\mu_X$  and  $\mu_X'$  are assumed to be 0.05 and  $\mu_Y'$  is equal to  $\mu_Y$  for algorithm 1; for algorithm 1 and 2, numerical integration was used. Liptak's method uses as weights the standardized expected differences with the standard error estimated (Liptak1) and the inverse of the standard error (Liptak2).

$\mu_Y'$	Fisher	Liptak1	Liptak2	alg. 1	alg. 2
0.01	0.157	0.201	0.141	0.202	0.203
0.02	0.166	0.187	0.158	0.198	0.189
0.03	0.203	0.207	0.200	0.211	0.209
0.04	0.233	0.230	0.227	0.242	0.236
0.05	0.275	0.264	0.266	0.273	0.270
0.06	0.331	0.328	0.322	0.340	0.334
0.07	0.384	0.386	0.372	0.395	0.390
0.08	0.469	0.475	0.444	0.493	0.489
0.09	0.535	0.559	0.506	0.575	0.570
0.10	0.602	0.637	0.565	0.648	0.646
0.11	0.671	0.703	0.612	0.719	0.717
0.12	0.736	0.772	0.673	0.786	0.781
0.13	0.796	0.838	0.717	0.847	0.846
0.14	0.841	0.876	0.768	0.882	0.881
0.15	0.893	0.920	0.817	0.923	0.951